Pohl O - Search Results

1

Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole.

Pohl O, Osterloh I, Lecomte V, Gotteland JP. Pohl O, et al. Int J Clin Pharmacol Ther. 2013 Jan;51(1):26-33. doi: 10.5414/CP201789. Int J Clin Pharmacol Ther. 2013. PMID: 23110788

2

Ulipristal acetate - safety and pharmacokinetics following multiple doses of 10-50 mg per day.

Pohl O, Osterloh I, Gotteland JP. Pohl O, et al. J Clin Pharm Ther. 2013 Aug;38(4):314-20. doi: 10.1111/jcpt.12065. Epub 2013 Apr 3. J Clin Pharm Ther. 2013. PMID: 23550906 Clinical Trial.

3

Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate.

Pohl O, Osterloh I, Gotteland JP. Pohl O, et al. J Clin Pharm Ther. 2013 Dec;38(6):512-7. doi: 10.1111/jcpt.12098. Epub 2013 Sep 16. J Clin Pharm Ther. 2013. PMID: 24102384 Clinical Trial.

4

A 39-week oral toxicity study of ulipristal acetate in cynomolgus monkeys.

Pohl O, Williams AR, Bergeron C, Gotteland JP. Pohl O, et al. Regul Toxicol Pharmacol. 2013 Jun;66(1):6-12. doi: 10.1016/j.yrtph.2013.02.013. Epub 2013 Mar 7. Regul Toxicol Pharmacol. 2013. PMID: 23474274

5

Carcinogenicity and chronic rodent toxicity of the selective progesterone receptor modulator ulipristal acetate.

Pohl O, Harvey PW, McKeag S, Boley SE, Gotteland JP. Pohl O, et al. Curr Drug Saf. 2013 Apr;8(2):77-97. doi: 10.2174/15748863112079990012. Curr Drug Saf. 2013. PMID: 23656453

6

The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.

Pohl O, Zobrist RH, Gotteland JP. Pohl O, et al. Reprod Sci. 2015 Apr;22(4):476-83. doi: 10.1177/1933719114549850. Epub 2014 Sep 16. Reprod Sci. 2015. PMID: 25228633 Free PMC article. Review.

7

Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age.

Pohl O, Bestel E, Gotteland JP. Pohl O, et al. Reprod Sci. 2014 Oct;21(10):1256-65. doi: 10.1177/1933719114522526. Epub 2014 Mar 6. Reprod Sci. 2014. PMID: 24604234 Clinical Trial.

8

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109.

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E. Pohl O, et al. J Clin Endocrinol Metab. 2018 Feb 1;103(2):497-504. doi: 10.1210/jc.2017-01875. J Clin Endocrinol Metab. 2018. PMID: 29216361 Clinical Trial.

9

Confirmation of the Cardiac Safety of PGF_2α Receptor Antagonist OBE022 in a First-in-Human Study in Healthy Subjects, Using Intensive ECG Assessments.

Täubel J, Lorch U, Coates S, Fernandes S, Foley P, Ferber G, Gotteland JP, Pohl O. Täubel J, et al. Among authors: pohl o. Clin Pharmacol Drug Dev. 2018 Nov;7(8):889-900. doi: 10.1002/cpdd.447. Epub 2018 Feb 28. Clin Pharmacol Drug Dev. 2018. PMID: 29489066 Free PMC article. Clinical Trial.

10

Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women.

Pohl O, Marchand L, Gotteland JP, Coates S, Täubel J, Lorch U. Pohl O, et al. Br J Clin Pharmacol. 2018 Aug;84(8):1839-1855. doi: 10.1111/bcp.13622. Epub 2018 Jun 5. Br J Clin Pharmacol. 2018. PMID: 29708281 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters